Summary (B351)
No statistically significant differences in primary efficacy variables
- Low placebo response rates:
- SGA of relief 22%
- SGA of abdominal discomfort/pain 19%
Significant treatment differences observed in daily diary variables
Consistent pattern of improvement for tegaserod across primary and secondary variables